cbdMD Inc (YCBD)

cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued MomentumMay 14, 2026 4:10 PM
PR Newswire (US) CHARLOTTE, N.C. , May 14, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most trusted CBD companies and operator of the cbdMD, Bluebird Botanicals, and Paw CBD brands, along with its THC beverage brand Oasis, today announced financial results for the second quarter of fiscal year 2026, ended March 31, 2026. The Company delivered 19% year-over-year and 12% sequential revenue growth, reflecting continued momentum in the core business and the contribution of newly acquired Bluebird Botanicals. Quarterly revenue, excluding revenue associated with the Bluebird acquisition, was the highest since our first fiscal quarter ending December 2023."This was a quarter of meaningful execution on multiple fronts," said Ronan Kennedy, CEO and CFO of cbdMD. "Our core business delivered another quarter of consistent growth, we successfully completed and integrated our first acquisition in years. The Bluebird Botanicals acquisition is a case study for what we can do — leveraging our infrastructure, marketing engine, and NYSE American listing to unlock value in a fragmented industry — and it sets the template for additional roll-up opportunities across hemp and adjacent health and wellness categories.""At the same time, the regulatory backdrop has shifted more in the last few months than in any period I can recall," Kennedy continued. "Multiple bipartisan legislative proposals are advancing, cannabis has been partially rescheduled, and CMS has opened the first federal Medicare pathway for hemp-derived CBD through the BEI program. We have been preparing for this moment for years. The launch of our clinical healthcare channel, our active engagement with ACOs, and our continued investment in patient science position cbdMD to participate meaningfully as adoption develops. We believe that as regulatory clarity continues to emerge, well-capitalized, compliance-focused operators with proven quality, safety data, and clinical credibility will be the ones that benefit — and that is precisely where cbdMD stands."Highlights for the Second Quarter of Fiscal 2026 and Notable Business UpdatesBluebird Botanicals integration on track. In mid-January 2026, cbdMD completed the strategic acquisition of Bluebird Botanicals, a long-standing and respected CBD brand. While acquisition and transition costs created an earnings drag during the quarter, Bluebird began generating positive income in March. Early third-quarter revenue is growing, and management expects the brand to contribute meaningfully to both top-line growth and earnings as additional products roll out and integration efficiencies are realized.CMS BEI Medicare pathway activated. Subsequent to quarter-end, on April 1, 2026, CMS, through the Center for Medicare & Medicaid Innovation, activated the BEI for eligible participants in select Innovation Center models, including the ACO REACH Model and the Enhancing Oncology Model. The optional BEI allows approved participants, subject to CMS requirements, safeguards, and physician oversight, to furnish eligible hemp-derived products to beneficiaries at up to $500 annually per eligible beneficiary. Eligible products include non-intoxicating full-spectrum hemp-derived CBD products containing up to 3 milligrams of naturally occurring THC per serving. The FDA has issued a limited enforcement-discretion letter providing additional regulatory clarity for eligible ingestible CBD products furnished through the BEI.cbdMD positioned as an evidence-based supplier of choice. cbdMD has launched a dedicated clinical healthcare channel to support the BEI pathway and is actively engaging ACOs, oncology practices, and health systems. The Company is continuing to invest in patient science to deepen the clinical evidence base supporting its products and to position itself as a trusted, evidence-based supplier as provider adoption develops. Management expects the early phase of the BEI to be implementation-led, with visibility into adoption developing through the second half of the calendar year. The program remains subject to ongoing legal and administrative scrutiny, including pending litigation, which the Company is actively monitoring.Bipartisan legislative momentum building. The Company continues to monitor and support bipartisan efforts to address the restrictive hemp legislation enacted in November 2025, including delay and comprehensive-framework proposals introduced in both the House and Senate. cbdMD believes that increased regulatory clarity — combined with the partial rescheduling of cannabis to Schedule III in April 2026 — will favor well-capitalized, compliance-focused operators with strong quality, safety, and clinical standards.Financial Highlights from our Second Quarter of Fiscal Year 2026:Net sales totaled $5.6 million in the second quarter of fiscal 2026 or an increase of 19% compared to $4.7 million in second quarter of fiscal 2025. Sequentially, revenue was up 12% from the first quarter of fiscal 2026.Our loss from operations was $801,000 in the second quarter of fiscal 2026 as compared to a loss of $485,000 in the prior year comparative period.Our non-GAAP adjusted EBITDA loss from operations in the second quarter of fiscal 2026 was approximately $220,000 compared to Adjusted EBITDA loss of $197,000 from operations in the second quarter of fiscal 2025.Net loss attributable to common shareholders for the second quarter of fiscal 2026 was approximately $0.88 million or a loss of $0.08 per share as compared to a net loss for the second quarter of fiscal 2025 of approximately $1.5 million, or $1.90 per share.At March 31, 2026 we had working capital of approximately $5.4 million and cash on hand of approximately $2.6 million as compared to working capital of approximately $3.3 million and cash on hand of approximately $2.2 million at September 30, 2025.We reported direct to consumer (DTC) net sales of $3.8 million or 67% of total net sales in the second quarter of fiscal 2026, an increase of $0.16 million, or 4% from the second quarter of fiscal 2025.We reported wholesale net sales of $1.8 million or 33% of total net sales in the second quarter of fiscal 2026, an increase of $0.73 million, or 65% from the second quarter of fiscal 2025.We will host a conference call at 4:20 p.m., Eastern Time, on Thursday, May 14, 2026, to discuss our March 31, 2026, second quarter of fiscal 2026 financial results and business progress.CONFERENCE CALL DETAILSThursday, May 14, 2026, 4:20 p.m. Eastern Time








USA/Canada: 888-880-3330Webcast/Webcast Replay link- available through May 14, 2027:
https://app.webinar.net/PGD52PJopeq








About cbdMD, Inc.cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced THC-free1 CBD products and an array of Farm Bill compliant Delta 9 products. To learn more about cbdMD as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, www.ATRxLabs.com, www.bluebirdbotanicals.com, or www.herbaloasis.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.
1THC-free is defined as below the level of detection using validated scientific analytical methods.Forward-Looking StatementsThis press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' ''proposes,'' ''will,'' ''could,'' ''would,'' ''potential,'' ''continue,'' ''seek,'' and similar expressions. These forward-looking statements include, but are not limited to, statements regarding: our ability to continue as a going concern; our expectations regarding revenue growth and stabilization of our core business; our ability to drive improved operating results and move closer to sustainable profitability; the expected benefits, synergies, and integration of the Bluebird Botanicals acquisition; our ability to unlock operational efficiencies, cost synergies, and revenue optimization; our expectations regarding regulatory clarity and its impact on our business; our belief that we are well-positioned to drive improved operating results; and our liquidity and working capital position. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: our ability to continue as a going concern and maintain adequate liquidity; our ability to increase revenues and achieve profitability; our ability to successfully integrate Bluebird Botanicals and realize anticipated synergies and benefits; changes in consumer demand for CBD and hemp-derived products; our ability to maintain compliance with NYSE American continued listing requirements; changes in federal and state laws and regulations governing hemp, CBD, and cannabis products, including the potential impact of restrictive hemp legislation; our ability to compete effectively in a highly competitive market; our ability to maintain and expand our distribution channels; our ability to develop and successfully launch new products; disruptions in our supply chain or manufacturing operations; our ability to protect our intellectual property; cybersecurity risks and data privacy concerns; our ability to attract and retain key personnel; general economic conditions and their impact on consumer spending; and other risks and uncertainties described under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as filed with the Securities and Exchange Commission (the "SEC") on December 18, 2025and our other filings with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligation to update any forward-looking statements except as required by applicable law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.1 THC-free is defined as below the level of detection using validated scientific analytical methods.Non-GAAP Financial MeasuresThis press release includes a financial measure that excludes the impact of certain items and therefore has not been calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). cbdMD, Inc. has included adjusted EBITDA because management uses this measure to assess operating performance in order to highlight trends in our business that may not otherwise be apparent when relying on financial measures calculated in accordance with GAAP. This non-GAAP financial measure should not be considered as an alternative to, or more meaningful than, net loss from operations as an indicator of our operating performance. Further, this non-GAAP financial measure, as presented by cbdMD, Inc., may not be comparable to similarly titled measures reported by other companies. cbdMD, Inc. has included below with this press release a reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure.cbdMD, INC.







CONDENSED CONSOLIDATED BALANCE SHEETS







MARCH 31, 2026 AND SEPTEMBER 30, 2025





















(unaudited)







March 31,
September 30,





2026
2025
Assets

























Cash and cash equivalents



$           2,635,243
$         2,261,242
Accounts receivable, net



1,573,101
1,040,887
Inventory, net



3,321,045
2,732,127
Inventory prepaid



331,694
214,795
Prepaid expenses and other current assets



520,110
302,378
Total current assets



8,381,193
6,551,429









Other assets:







Property and equipment, net



361,119
277,377
Operating lease assets



361,558
703,934
Deposits for facilities



62,708
62,708
Intangible assets, net



2,193,271
2,124,502
Goodwill



190,000
-
Investment in other securities, noncurrent



700,000
700,000
Total other assets



3,868,656
3,868,521









Total assets



$         12,249,849
$       10,419,950
CONSOLIDATED BALANCE SHEETS
















MARCH 31, 2026 AND SEPTEMBER 30, 2025







(continued)






























March 31,
September 30,





2026
2025
Liabilities and shareholders' equity













Current liabilities:






Accounts payable


$           1,393,402
$         1,173,642
Accrued expenses


626,722
735,672
Accrued dividends



78,805
-
Deferred revenue



454,039
506,289
Operating leases - current portion



407,811
778,240
Note payable



7,321
-
Total current liabilities

2,968,100
3,193,843









cbdMD, Inc. shareholders' equity:







Preferred stock, authorized 50,000,000 shares, $0.001







par value, 1,591,210 and 1,700,000 shares issued and outstanding, respectively



1,591
1,700Common stock, authorized 150,000,000 shares, $0.001







par value, 10,070,560 and 8,917,054  shares issued and outstanding, respectively



10,496
8,917Additional paid in capital



189,909,199
186,650,640
Accumulated deficit



(180,636,537)
(179,435,150)
Total cbdMD, Inc. shareholders' equity



9,284,749
7,226,107
















Total liabilities and shareholders' equity
$         12,252,849
$       10,419,950
 cbdMD, INC.






CONSOLIDATED STATEMENTS OF OPERATIONS






FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025






(unaudited)
















Three months ended March 31,
Six months ended March 31,





2026
2025
2026
2025













Gross Sales



$           5,640,059
$         4,749,426
$ 10,656,964
$       9,862,902
Total Net Sales



$           5,640,059
$         4,749,426
$ 10,656,964
$       9,862,902
Cost of sales



$           2,383,137
$         1,790,062
$   4,398,751
$       3,502,929
Gross Profit



$           3,256,922
$         2,959,364
$   6,258,213
$       6,359,973













Operating expenses



$           4,057,706
$         3,445,180
$   7,345,287
$       6,932,061
Loss from operations



$             (800,784)
$           (485,816)
$  (1,087,074)
$         (572,088)
Decrease (increase) in fair value of convertible debt



$                          -
$               (2,583)
$                  -
$            87,380
Interest expense (income)



$                  2,806
$                7,642
$          5,963
$            19,046
Loss before provision for income taxes



$             (797,978)
$           (480,757)
$  (1,081,111)
$         (465,662)













Net (loss) income



$             (797,978)
$           (480,757)
$  (1,081,111)
$         (465,662)













Preferred dividends



$                78,805
$         1,000,500
$      120,276
$       2,001,001













Net Loss attributable to cbdMD, Inc. common shareholders



$             (876,783)
$        (1,481,257)
$  (1,201,387)
$      (2,466,663)













Net Loss per share:











Basic and diluted earnings per share



$                   (0.08)
$                 (1.90)
$           (0.12)
$               (3.67)
Weighted average number of shares Basic and Diluted:



10,443,617
778,410
9,715,873
672,558








 cbdMD, INC.CONSOLIDATED STATEMENT OF CASH FLOWSFOR THE SIX MONTHS ENDED MARCH 31, 2026 AND 2025(unaudited)









March 31,
March 31,



2026
2025







Cash flows from operating activities:





Net Loss

$       (1,081,111)
$             (465,662)
Adjustments to reconcile net loss to net





cash used by operating activities:





Restricted stock expense

$            296,950
$                  2,868
Issuance of stock for services

$                        -
$                82,250
Intangibles amortization

$            398,126
$              382,534
Depreciation

$              98,866
$              201,369
Decrease in fair value of convertible debt

$                        -
$               (87,380)
Amortization of operating lease asset

$            342,376
$              330,969
Changes in operating assets and liabilities:





Accounts receivable

$          (511,168)
$               (67,408)
Inventory

$          (325,720)
$             (297,518)
Prepaid inventory

$          (116,899)
$               (62,623)
Prepaid expenses and other current assets

$          (110,764)
$               (62,361)
Accounts payable and accrued expenses

$          (121,059)
$             (277,135)
Operating lease liability

$          (370,428)
$             (241,489)
Deferred revenue / customer deposits

$            (34,133)
$                54,160
Cash flows from operating activities

$       (1,534,964)
$             (507,426)







Cash flows from investing activities:





Purchase of property and equipment

$          (170,550)
$             (179,893)
Purchase of Bluebird

$             56,427
$                          -
Cash flows from investing activities

$          (114,123)
$             (179,893)







Cash flows from financing activities:





Proceeds from issuance of preferred stock

$        2,026,088
$                          -
Cash flows from financing activities

$        2,026,088
$                          -
Net increase (decrease) in cash

$           377,001
$             (687,319)
Cash and cash equivalents, beginning of period

$        2,261,242
$           2,452,553
Cash and cash equivalents, end of period

$        2,638,243
$           1,765,234





















Supplemental Disclosures of Cash Flow Information:








2026
2025







Cash Payments for:





Interest expense



$                19,046







Non-cash financing/investing activities:





Issuance of shares for conversion of debt and accrued interest

$                        -
$           1,079,639
All stock purchase of Bluebird

$            936,992
$                          -
Issuance of shares for service

$                        -
$                82,250
Preferred dividends accrued but not paid

$              78,805
$           2,001,000







 cbdMD, Inc.




NON GAAP ADJUSTED EBITDA




FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2026 AND 2025




(unaudited)























Three months ended March 31,
Six months ended March 31,



2026
2025
2026
2025











GAAP (loss) from operations

$          (800,784)
$              (485,816)
$        (1,087,074)
$      (572,088)
Adjustments:









Depreciation and Amortization (1)

$            251,550
$               285,896
$             496,992
$       583,903
Employee and director stock compensation (2)

$            296,872
$                   1,934
$             301,804
$           5,016
Mergers and Acquisitions and financing transaction expense (3)

$              31,671
$                           -
$               53,688
$                   -
Non-GAAP adjusted EBITDA

$           (220,691)
$              (197,986)
$            (234,590)
$         16,831











(1) Represents depreciation of property, plant and equipment and amortization of the Company's intangible assets.






(2) Represents non-cash expense related to options, warrants, restricted stock expenses that have been amortized during the period.




(3) Represents costs associated with the Bluebird acquisition.









Contacts:Investors:
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer

cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter ResultsMay 12, 2026 3:02 PM
PR Newswire (US) CHARLOTTE, N.C., May 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Thursday, May 14, 2026, to discuss the company's March 31, 2026 second quarter financial results and business progress. CONFERENCE CALL DETAILSThursday, May 14, 2026, 4:20 p.m. Eastern Time

USA/Canada:888-880-3330



Webcast/Webcast Replay link - available through May 14, 2027:https://app.webinar.net/PGD52PJopeq


 About cbdMD, Inc.cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced THC-free1 CBD products and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products and our ATRx brand features functional mushroom products. In addition, we operate Herbal Oasis, a premium, award winning THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection. With an alcohol-free formula and wellness-forward ingredients, Oasis invites a better way to drink-one rooted in clarity, balance, and joy. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD and Full Spectrum products as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, ATRxlabs.com, www.bluebirdbotanicals.com, or Herbaloasis.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.
(1) THC-free is defined as below the level of detection using validated scientific analytical methods.Contact Information:cbdMD, Inc.
Ronan Kennedy, CEO and CFO
Phone: +1 (704) 445-3064
email: IR@cbdmd.com View original content to download multimedia:https://www.prnewswire.com/news-releases/cbdmd-inc-to-host-conference-call-to-discuss-march-31-2026-second-quarter-results-302770002.htmlSOURCE cbdMD, Inc. Original: cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results

YCBD...$1.19...🥳... 70s /80s looking better here...$1.09s not so much...

georgie18

Re: georgie18 post# 551

Wednesday, April 22, 2026 1:27:39 PM

Post#
557
of 557
YCBD...$1.04...🥳...70s /80s looking better here...$1.09s not so much...

georgie18

Re: georgie18 post# 550

Friday, January 23, 2026 10:55:24 AM

Post#
551
of 556
YCBD...80...Added here...🥳

georgie18

Member Level
Re: georgie18 post# 711273

Friday, January 16, 2026 3:46:52 PM

Post#
711980
of 712606
YCBD...92...🥳...Adding and bidding 70s...

georgie18

Member Level
Re: None

Monday, January 12, 2026 12:32:02 PM

Post#
402770
of 403080
YCBD...$1.09...🥳...Nice spot to start accumulating this Pot Stock...will add up or down...

YCBD...$1.04...🥳...70s /80s looking better here...$1.09s not so much...

georgie18

Re: georgie18 post# 550

Friday, January 23, 2026 10:55:24 AM

Post#
551
of 556
YCBD...80...Added here...🥳

georgie18

Member Level
Re: georgie18 post# 711273

Friday, January 16, 2026 3:46:52 PM

Post#
711980
of 712606
YCBD...92...🥳...Adding and bidding 70s...

georgie18

Member Level
Re: None

Monday, January 12, 2026 12:32:02 PM

Post#
402770
of 403080
YCBD...$1.09...🥳...Nice spot to start accumulating this Pot Stock...will add up or down...

cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in MedicareApril 1, 2026 8:30 AM
PR Newswire (US)

Company brings one of the only combined clinical and toxicological safety dataset in the hemp-derived CBD category into a new provider channel as CMS activates cannabinoid access within value-based care modelsCHARLOTTE, N.C., April 1, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leader in science-driven cannabinoid products, today announced the launch of its clinical healthcare channel, positioning the Company to support physicians, health systems, and value-based care organizations as federal policy establishes structured pathways for hemp-derived cannabinoid products within Medicare programs.







On March 20, 2026, the Centers for Medicare & Medicaid Services (CMS) published operational guidance activating the Substance Access Beneficiary Engagement Incentive (BEI), an existing incentive mechanism within CMS Innovation Center models, to include eligible hemp-derived cannabinoid products for the first time. Effective April 1, 2026, participating accountable care organizations and oncology practices in select models, including the Enhancing Oncology Model (EOM) and ACO REACH, may furnish eligible hemp-derived products to Medicare patients as part of physician-supervised care. The upcoming LEAD Model also incorporates the BEI framework when it is expected to launch on January 1, 2027. Together these models encompass thousands of physicians and millions of aligned Medicare beneficiaries.The BEI remains a limited, model-specific initiative, not a broad access or reimbursement program, and participating organizations independently determine supplier relationships."Healthcare is where this category has always needed to go," said Ronan Kennedy, Chief Executive Officer of cbdMD. "This is the inflection point. CMS has established a structured, physician-supervised framework for hemp-derived cannabinoids within Medicare, and the bar to participate credibly is high requiring clinical data, institutional-grade documentation and healthcare supply infrastructure. cbdMD has spent years preparing for such framework."cbdMD is entering the clinical channel with a scientific and regulatory platform the Company believes is unmatched in the hemp-derived CBD category. To the Company's knowledge, no other hemp-derived CBD manufacturer has published both OECD-standard preclinical toxicology data and human randomized controlled trial data for its commercial product lines. That foundation includes:Published preclinical safety data: A 90-day subchronic oral toxicity study conducted to OECD 408 guidelines, the international standard used in pharmaceutical safety assessment, demonstrating safety margins significantly above expected human dosing levels
 Human clinical evidence: Data from an IRB-approved, randomized, double-blind, placebo-controlled trial confirming safety and tolerability in human subjects
 GRAS regulatory status: Self-affirmed Generally Recognized As Safe (GRAS) dossiers supporting key product categories,the same safety standard applied to conventional food and supplement ingredients reviewed by the FDA
 Healthcare-grade supply chain: Batch-level traceability, certificate of analysis documentation, and quality systems designed for institutional procurement and compliance reviewIn parallel, cbdMD is developing a dedicated provider-focused product line with formulations, documentation, and labeling structured specifically for clinical environments, along with infrastructure to support multi-site health systems and value-based care organizations."We recognize physicians and health systems evaluating this category will not accept consumer-grade marketing claims or products without published safety data," said Sibyl Swift, Ph.D., member of board of directors and scientific consultant of cbdMD. "They require OECD-standard toxicology, human clinical data, drug interaction transparency, and documentation that can withstand institutional review. That evidence base does not exist broadly in this category, cbdMD has built it. That is where we are focused."The Company is actively engaging accountable care organizations, oncology practices, and health systems as they evaluate implementation under the BEI and broader clinical integration of cannabinoid products. cbdMD believes that provider adoption in this channel will be driven by demonstrated safety, data transparency, and operational reliability; standards the Company has been building toward for years. The company is also pursuing research partnerships with healthcare organizations and academic institutions to generate real-world outcomes data on hemp CBD in physician-supervised Medicare settings.cbdMD is also monitoring the FDA's recent submission of updated regulatory considerations for hemp-derived CBD products to the White House Office of Information and Regulatory Affairs, which the Company views as part of a continued shift toward a more clearly defined, evidence-based federal framework for cannabinoid products.Healthcare organizations interested in cbdMD's clinical channel, product documentation, or supply capabilities are encouraged to contact the Company directly.Clinical channel inquiries: md@cbdmd.comAbout the CMS Substance Access BEI The Substance Access Beneficiary Engagement Incentive, effective April 1, 2026, allows participating organizations in CMS Innovation Center models — including ACO REACH, the Enhancing Oncology Model, and the upcoming LEAD Model — to furnish eligible hemp-derived CBD products to Medicare patients through physician-supervised consultations. CMS does not reimburse product costs, does not designate preferred or approved suppliers, and does not cover products as a Medicare benefit. Participating organizations make independent clinical and procurement decisions.About cbdMD, Inc. cbdMD, Inc. (NYSE American: YCBD) is a science-driven cannabinoid company offering a portfolio of hemp-derived CBD products under the cbdMD, Bluebird Botanicals, Paw CBD, and Herbal Oasis brands. The Company has invested in clinical research, toxicological safety studies, and GRAS regulatory dossiers, establishing what it believes is the most comprehensive published safety and clinical dataset in the U.S. hemp-derived CBD category. cbdMD products are available direct-to-consumer at cbdmd.com, through thousands of retail locations, and through the Company's newly launched clinical healthcare channel. Learn more at cbdmd.com.Forward Looking StatementsThis press release contains statements, estimates, forecasts, and projections regarding future performance and events that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Those statements include statements regarding expectations from evolving federal regulation, the development of cbdMD's clinical healthcare channel and platform, Medicare requirements, market acceptance of CBD clinical healthcare products and the ability of cbdMD to furnish eligible hemp-derived CBD products to Medicare patients. These statements may be identified by the use of words like "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "will," "should," and "seek," and similar expressions and include any financial projections or estimates or pro forma financial information set forth herein. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those projected in the forward-looking statements. Important factors and risks that could cause actual results to differ materially from our expectations include, but are not limited to, participating organizations in CMS Innovation Center models acceptance of eligible hemp-derived CBD products to be furnished to Medicare patients; customer, professional healthcare provider and Medicare acceptance of our product offerings; and costs and expenses to develop a clinical healthcare channel and products, as well as those risks detailed in our filings with the SEC, including our most recent Form 10-K and other filings with the SEC.Contact Information: Investors:
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer

cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026February 17, 2026 4:10 PM
PR Newswire (US)

CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025.







cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We are encouraged by our return to sequential revenue growth and the continued stabilization of our core business," said Ronan Kennedy, CEO and CFO of cbdMD. "This quarter reflects several consecutive months of improving trends, including our strongest December and January in the past three years. With a stronger balance sheet, disciplined cost structure, and the addition of Bluebird Botanicals, we believe we are increasingly well positioned to drive improved operating results.""The acquisition of Bluebird Botanicals represents a meaningful step forward for cbdMD. In addition to expanding our revenue base, Bluebird brings valuable intellectual property and regulatory assets, including GRAS status for full-spectrum CBD. As we integrate operations during the second fiscal quarter, we are focused on unlocking synergies and driving incremental earnings. We believe these actions position us to continue improving operating results and attain to sustainable profitability."In addition to announcing its financial results, the Company also recently filed a definitive proxy statement for its 2026 annual meeting, scheduled March 30, 2026. Shareholders of record as of February 2, 2026 will be eligible to vote.Highlights for the First Quarter of Fiscal 2026 and Notable Business Updates In December 2025, the Company raised approximately $2.25 million in Series C preferred financing, enhancing liquidity and working capital to support ongoing operations and integration efforts.In mid-January 2026, cbdMD completed the strategic acquisition of Bluebird Botanicals, a long-standing and respected CBD brand. The transaction includes Bluebird's e-commerce business and select intellectual property, including GRAS status for full-spectrum CBD formulations. Integration is underway, with a focus on operational efficiencies, cost synergies, and revenue optimization. The Company continues to monitor and support bipartisan efforts to address restrictive hemp legislation introduced in November 2025. cbdMD believes that increased regulatory clarity will favor well-capitalized, compliance-focused operators with strong quality and safety standards.Financial Highlights from our First Quarter of Fiscal Year 2026:Net sales totaled $5.0 million in the first quarter of fiscal 2026 or a decrease of 1.9% compared to $5.1 million in first quarter of fiscal 2025. Sequentially, revenue was up 12% from the fourth quarter of fiscal 2025.Our loss from operations was $286,000 in the first quarter of fiscal 2026 as compared to a loss of $86,000 in the prior year comparative period.Our non-GAAP adjusted EBITDA loss from operations in the first quarter of fiscal 2026 was approximately $36,000 compared to Adjusted EBITDA of $214,000 from operations in the first quarter of fiscal 2025.Net loss attributable to common shareholders for the first quarter of fiscal 2026 was approximately $0.32 million or a loss of $0.04 per share as compared to a net loss for the first quarter of fiscal 2025 of approximately $1.0 million, or $1.73 per share.At December 31, 2025, we had working capital of approximately $5.4 million and cash on hand of approximately $3.4 million as compared to working capital of approximately $3.3 million and cash on hand of approximately $2.2 million at September 30, 2025.We reported direct to consumer (DTC) net sales of $3.6 million or 72% of total net sales in the first quarter of fiscal 2026, a decrease of $0.35 million, or 9% from the first quarter of fiscal 2025.We reported wholesale net sales of $1.4 million or 21% of total wholesale net sales in the first quarter of fiscal 2026, an increase of $0.25 million, or 22% from the first quarter of fiscal 2025.We will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss our December 31, 2025, first quarter of fiscal 2026 financial results and business progress.CONFERENCE CALL DETAILSTuesday February 17, 2026, 4:20 p.m. Eastern TimeUSA/Canada:888-880-3330Webcast/Webcast Replay link- available through February17, 2027: https://app.webinar.net/YzX7D4ynvN2About cbdMD, Inc.cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced THC-free1 CBD products and an array of Farm Bill compliant Delta 9 products. To learn more about cbdMD as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, www.ATRxLabs.com, www.bluebirdbotanicals.com, or www.herbaloasis.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.
1THC-free is defined as below the level of detection using validated scientific analytical methods.Forward-Looking StatementsThis press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' ''proposes,'' ''will,'' ''could,'' ''would,'' ''potential,'' ''continue,'' ''seek,'' and similar expressions. These forward-looking statements include, but are not limited to, statements regarding: our ability to continue as a going concern; our expectations regarding revenue growth and stabilization of our core business; our ability to drive improved operating results and move closer to sustainable profitability; the expected benefits, synergies, and integration of the Bluebird Botanicals acquisition; our ability to unlock operational efficiencies, cost synergies, and revenue optimization; our expectations regarding regulatory clarity and its impact on our business; our belief that we are well-positioned to drive improved operating results; and our liquidity and working capital position. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: our ability to continue as a going concern and maintain adequate liquidity; our ability to increase revenues and achieve profitability; our ability to successfully integrate Bluebird Botanicals and realize anticipated synergies and benefits; changes in consumer demand for CBD and hemp-derived products; our ability to maintain compliance with NYSE American continued listing requirements; changes in federal and state laws and regulations governing hemp, CBD, and cannabis products, including the potential impact of restrictive hemp legislation; our ability to compete effectively in a highly competitive market; our ability to maintain and expand our distribution channels; our ability to develop and successfully launch new products; disruptions in our supply chain or manufacturing operations; our ability to protect our intellectual property; cybersecurity risks and data privacy concerns; our ability to attract and retain key personnel; general economic conditions and their impact on consumer spending; and other risks and uncertainties described under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as filed with the Securities and Exchange Commission (the "SEC") on December 18, 2025, our Quarterly Report on Form 10-Q for the quarter ended December 31, 2025, and our other filings with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligation to update any forward-looking statements except as required by applicable law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.1 THC-free is defined as below the level of detection using validated scientific analytical methods.No Offer or SolicitationThis press release is for informational purposes only and shall not constitute a solicitation of a proxy, consent or authorization with respect to the Company's 2026 annual meeting. This communication may be deemed to be solicitation material in respect of the annual meeting proposals. In connection with the annual meeting proposals, the Company has filed a definitive proxy statement with the SEC and commenced mailing of the definitive proxy statement to its record shareholders, and the Company may file other documents with the SEC regarding the proposals in the proxy statement. THE COMPANY'S SHAREHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS CAREFULLY IN THEIR ENTIRETY, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSALS.Non-GAAP Financial MeasuresThis press release includes a financial measure that excludes the impact of certain items and therefore has not been calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). cbdMD, Inc. has included adjusted EBITDA because management uses this measure to assess operating performance in order to highlight trends in our business that may not otherwise be apparent when relying on financial measures calculated in accordance with GAAP. This non-GAAP financial measure should not be considered as an alternative to, or more meaningful than, net loss from operations as an indicator of our operating performance. Further, this non-GAAP financial measure, as presented by cbdMD, Inc., may not be comparable to similarly titled measures reported by other companies. cbdMD, Inc. has included below with this press release a reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure.Contacts:Investors:
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer

YCBD....................................https://stockcharts.com/sc3/ui/?s=YCBD&p=W&b=5&g=0&id=p86431144783

cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter ResultsFebruary 12, 2026 5:31 PM
PR Newswire (US)

CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress.







CONFERENCE CALL DETAILSTuesday, February 17, 2026, 4:20 p.m. Eastern TimeUSA/Canada: 888-880-3330Webcast/Webcast Replay link - available through February 17, 2027:https://app.webinar.net/YzX7D4ynvN2About cbdMD, Inc.cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced THC-free1 CBD products and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products and our ATRx brand features functional mushroom products. In addition, we operate Herbal Oasis, a premium, award winning THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection. With an alcohol-free formula and wellness-forward ingredients, Oasis invites a better way to drink-one rooted in clarity, balance, and joy. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD and Full Spectrum products as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, ATRxlabs.com, www.bluebirdbotanicals.com, or Herbaloasis.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.
(1) THC-free is defined as below the level of detection using validated scientific analytical methods.Contact Information:cbdMD, Inc.
Ronan Kennedy, CEO and CFO
Phone: +1 (704) 445-3064
email: IR@cbdmd.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/cbdmd-inc-to-host-conference-call-to-discuss-december-31-2025-first-quarter-results-302686995.htmlSOURCE cbdMD, Inc.

Original: cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

cbdMD Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation PathwaysJanuary 29, 2026 12:53 PM
PR Newswire (US)

CHARLOTTE, N.C., Jan. 29, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading innovator in hemp-derived wellness products, today announced a strategic initiative to integrate and expand its regulatory science, safety, and intellectual property assets to establish a differentiated cannabinoid compliance and evidence platform aligned with evolving federal healthcare evaluation frameworks, including emerging CMS and CMMI innovation initiatives.







The program combines scientific and regulatory assets acquired through cbdMD's recent acquisition of Bluebird Botanicals ("Bluebird") with cbdMD's existing clinical and toxicology foundation, creating what management believes is one of the most comprehensive safety and regulatory dossiers spanning both broad-spectrum and full-spectrum cannabinoid formulations.In early January 2026, cbdMD acquired substantially all assets of Bluebird, a pioneer in hemp-derived wellness products known for scientific discipline and proactive regulatory engagement. While Bluebird represents an estimated 10% step in revenue growth, among the acquired assets is Bluebird's established self-affirmed GRAS (Generally Recognized As Safe) determination for a full-spectrum hemp extract containing naturally occurring THC—one of the industry's most established safety evaluations for a full-spectrum cannabinoid formulation.The acquisition builds upon cbdMD's own science-backed platform, including peer-reviewed human clinical research supporting the safety and efficacy of its proprietary broad-spectrum cannabidiol formulations, as well as extensive preclinical and sub chronic toxicology work.Integrated GRAS and Regulatory Science ProgramAs part of cbdMD's strategic initiative and in furtherance of the Bluebird acquisition, cbdMD is launching an integrated GRAS and regulatory science program to consolidate, modernize, and strengthen its combined science portfolio. Importantly, the program is expected to be executed primarily through cbdMD's internal scientific, quality, and regulatory organization, enabling efficient advancement of high-value regulatory assets with minimal reliance on costly outside consultants.Key objectives include the preparation of a new self-affirmed GRAS determination for cbdMD's broad-spectrum formulations and continued strengthening of Bluebird's existing full-spectrum GRAS dossier under a unified regulatory strategy."We are intentionally building a durable regulatory-grade foundation designed for the next era of federal regulation and scrutiny and opportunity," said Ronan Kennedy, CEO of cbdMD. "By integrating Bluebird's established GRAS work with cbdMD's clinical and toxicology platform—and advancing both through a highly cost-efficient internal regulatory science strategy—we believe cbdMD is well-positioned to engage credibly with regulators, the medical community, and healthcare innovation stakeholders as CMS and CMMI evaluation frameworks continue to evolve."About cbdMD, Inc.cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most recognized cannabidiol (CBD) brands, offering a comprehensive line of U.S.-produced THC-free¹ CBD products and an array of Farm Act-compliant Delta-9 products. The Company also operates Bluebrid Botanicals, Paw CBD, ATRx Labs, and Herbal Oasis, a premium THC-infused functional social seltzer. Learn more at cbdmd.com , www.pawcbd.com, www.bluebirdbotanicals.com, ATRxlabs.com, or Herbaloasis.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.Forward-Looking StatementsThis press release contains statements, estimates, forecasts, and projections regarding future performance and events that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Those statements include statements regarding expectations from the integration of Bluebird Botanicals, evolving federal regulation, anticipated long-term growth strategy, potential efficiencies resulting from the Bluebird Botanicals acquisition and Bluebird Botanicals IP.  These statements may be identified by the use of words like "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "will," "should," and "seek," and similar expressions and include any financial projections or estimates or pro forma financial information set forth herein.  Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those projected in the forward-looking statements.  Important factors and risks that could cause actual results to differ materially from our expectations include, but are not limited to, regulatory issues, IP development, unexpected issues with integrating the two companies, and customer acceptance of our product offerings, as well as those risks detailed in our filings with the SEC, including our most recent Form 10-K and other filings with the SEC.1 THC-free is defined as below the level of detection using validated scientific analytical methods.Contact Information:
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer

YCBD...80...Added here...🥳

georgie18

Member Level
Re: georgie18 post# 711273

Friday, January 16, 2026 3:46:52 PM

Post#
711980
of 712606
YCBD...92...🥳...Adding and bidding 70s...

georgie18

Member Level
Re: None

Monday, January 12, 2026 12:32:02 PM

Post#
402770
of 403080
YCBD...$1.09...🥳...Nice spot to start accumulating this Pot Stock...will add up or down...

YCBD...92...🥳...Adding and bidding 70s...

georgie18

Member Level
Re: None

Monday, January 12, 2026 12:32:02 PM

Post#
402770
of 403080
YCBD...$1.09...🥳...Nice spot to start accumulating this Pot Stock...will add up or down...

YCBD...$1.09...🥳...Nice spot to start accumulating this Pot Stock...will add up or down...

BUY BUY BUy before trumps EO in jan.

The $1.6's are nearing.

In at these favorable levels.

HAULTED. No one knows why.

It's buying time at these lows. imo.

Dumb time. Let's see how down it will drop. Maybe until tomorrow in the $1 lows.

YCBD...$2.49...🥳...Zero Borrow Shares Available...

YCBD...................................................p/m

$2.23

Let's go to $6 here 

They got all their ducks in a row.This will blow soon.Nothing but good news.

YCBD........................................https://stockcharts.com/sc3/ui/?s=YCBD&p=W&b=5&g=0&id=p86431144783

1.10

)1.03 little better then yesterday exit

Cash out only speculation 

Speculation 

.80

Get high now .72

ycbd..................................https://stockcharts.com/sc3/ui/?s=YCBD&p=W&b=5&g=0&id=p86431144783

The CBD companies have all been eliminated with the latest legislation.

YCBD.......................https://stockcharts.com/h-sc/ui?s=YCBD&p=W&b=5&g=0&id=p86431144783

YCBD....................................................https://stockcharts.com/h-sc/ui?s=YCBD&p=W&b=5&g=0&id=p86431144783

, North Carolina--(Newsfile Corp. - June 24, 2025) - cbdMD, Inc. (NYSE American: YCBD), a trusted leader in the wellness and cannabinoid industry, is proud to announce the retail debut of its Herbal Oasis Social Tonics at select Total Wine in Charlotte and surrounding North Carolina areas. The premium line of hemp-derived THC seltzers, first launched in late 2024, is now available across Total Wine stores across North Carolina.
With strong initial placement in the Charlotte metro, the company is signaling its commitment to expanding Oasis Social Tonics throughout the state.

Designed for mindful socialization, Herbal Oasis Social Tonics combine hemp-derived THC and CBG with a nootropic blend of functional mushrooms and adaptogens-including Lion's Mane, Reishi, Cordyceps, and Maitake-offering consumers an alternative to traditional alcoholic beverages that delivers calm energy and social clarity. Available in four vibrant flavors-Berry Fusion, Lemon Lift, Mango Bliss, and Tropical Twist-each can is low-calorie and infused with L-theanine and B12 for a refreshing, feel-good experience.

We're thrilled to see Oasis Social Tonics reaching retail shelves through trusted partners like Total Wine," said CEO Ronan Kennedy. "This is a key step in our broader strategy to activate across the South East and bring our elevated social experience to consumers in more markets."

For more information about Oasis Social Tonics, visit www.herbaloasis.com.

About Herbal Oasis

Herbal Oasis is a premium THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection. With an alcohol-free formula and wellness-forward ingredients, Oasis invites a better way to drink-one rooted in clarity, balance, and joy. More information about Oasis Social Tonics can be found at www.herbaloasis.com. Oasis is a subsidiary of cbdMD, Inc.
www.herbaloasis.com

www.herbaloasis.com

https://finance.yahoo.com/news/herbal-oasis-expands-footprint-distribution-110000762.html

https://finance.yahoo.com/news/cbdmd-inc-ycbd-q2-2025-071333002.html

https://finance.yahoo.com/news/cbdmd-inc-announces-automatic-conversion-002000906.html

https://finance.yahoo.com/news/herbal-oasis-wins-national-recognition-110000232.html

WQLF SAYS; So just the opposite happened. The added 3 million common shares since the 1:6 preferred shares was declined, in my opinion it appears that the company had to find a way to get the majority of the common shareholders to vote in the affirmative for the 1:13 offer and a Reverse split. Why would common shareholders vote for such nonsense and have their shares diluted? Why would the institutional lenders convert their preferred for common shares when they can get more for their preferreds in the short run? Were they an inside plant by those preferred shareholders that would benefit from a 1:13 conversion in order to get a majority of the common shareholders to vote for the conversion? Who would benefit the most for a 1:13 conversion, besides the CEO and some of the directors? What a shame for those that run this company in my opinion of course…Have Mercy WQLF Ahooooooo

Charlotte, North Carolina--(Newsfile Corp. - April 8, 2025) - Herbal Oasis ("Oasis"), the hemp derived THC-infused social seltzer brand redefining how people connect, unwind, and celebrate life, is proud to announce that starting in late March, Oasis began arriving on shelves across Alabama and select counties in the Florida Panhandle, making it easier for people to grab Oasis's premium, alcohol-free beverage made for presence, clarity, and connection.“

https://finance.yahoo.com/news/herbal-oasis-announces-distribution-agreement-151900766.html

Delayed FDA action on CBD faces scrutiny as House hearing revives regulatory hopes
April 7, 2025 / CBD, Food & Drink, News, North America, Regulatory, USA

https://hemptoday.net/delayed-fda-action-on-cbd-faces-scrutiny-as-house-hearing-revives-regulatory-hopes/

WQLF SAYS:

“Novel Food dossier (RP793) has advanced to the last phase of regulatory assessment with the UK Food Standards Agency (FSA), nearing final approval.”

https://finance.yahoo.com/news/cbdmd-achieves-key-milestone-uk-110000318.html

https://finance.yahoo.com/news/cbdmd-inc-ycbd-q1-2025-072032753.html

https://www.sec.gov/Archives/edgar/data/1644903/000143774925004928/0001437749-25-004928-index.htm

.30s good buys play it and dump it before April 9th as a low float play 

WQLF SAYS: MAXIM GROUP

https://www.maximgrp.com/home

Maxim Group CBDMD

“Maxim Group initiated coverage of cbdMD (AMEX: YCBD) with a Buy recommendation on October 5, 2023. Maxim Group LLC acted as the sole book-running manager for cbdMD's underwritten public offering of 1,350,000 shares of its common stock at a public offering price of $2.10 per share. The offering closed on May 3, 2023, with gross proceeds of approximately $2.8 million before deducting underwriting discounts and commissions and offering expenses.“


Maxim Group CV Sciences

CV Sciences, Inc. appointed Maxim Group LLC as a non-exclusive financial advisor and investment banker to provide strategic financial advisory and investment banking services. The company intends to continue building an efficient and cost-effective consumer products platform and evaluate inbound and outbound merger, sale, acquisition, or other options for the company with the help of Maxim Group.
CV Sciences, Inc. reported its second quarter 2024 financial results, showing stable revenue of $4.0 million, consistent with the second quarter of 2023 and the first quarter of 2024. The company achieved a gross margin of 47.0%, its best in 13 quarters, up from 43.3% in the second quarter of 2023.
Maxim Group LLC: Appointed as a non-exclusive financial advisor and investment banker to CV Sciences, Inc. to provide strategic financial advisory and investment banking services.
CV Sciences, Inc.: A consumer wellness company specializing in nutraceuticals and plant-based foods. The company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C.
Elevated Softgels: A leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry, recently acquired by CV Sciences, Inc..
Joseph Dowling: Chief Executive Officer of CV Sciences, Inc., who stated that the company's second quarter 2024 progress demonstrates a continuous commitment to innovation and cost-efficient execution as they move closer to profitability and positive cash flow.
Maxim Moinat: Has a background in bioinformatics and medical natural sciences, but is not directly related to the appointment of Maxim Group LLC to CV Sciences, Inc..
Maxim Pospelov: A professor in the Physics department at the University of Minnesota, unrelated to CV Sciences, Inc. or Maxim Group LLC.
Maxim Kholin: Director and Co-founder of Gero, a company focused on drug discovery and longevity research, unrelated to CV Sciences, Inc. or Maxim Group LLC.
Laura Maxim: A researcher at the CNRS Institute for Communication Sciences, her work focuses on the production and communication of scientific knowledge on chemical risks, unrelated to CV Sciences, Inc. or Maxim Group LLC.


MAXIM GROUP CHARLOTTES WEB

WQLF Analysis continued

The shares added to the outstanding since the Quarter ending on September 30, 2024 included 1,421,067 common shares converted from notes. There was 175,000 issued for consultants. These shares were added to the float along with the 719,709 shares by the 5 investors after the failed 3:1 preferred conversion proposal and the 6:1 proposal. Why would the note holders and the 5 investors convert to common shares of their shares would be wiped out from a 13:1 preferred share conversion? I will bet they converted to make sure the 13:1 and the reverse split are voted down.

WQLF ANALYSIS :

Double Wammy. Not only did the company deter the common shareholders to vote no to the preferred conversion of 13:1, they also wanted the common shareholders to vote for a 1:3 or 1:10 reverse split. Both proposals surely to guarantee a no vote for both proposals. Could that be the reason the common shareholders didn’t sell off after hours? I do think so in my opinion from my analysis and common sense. Let’s take a look at the outstanding shares from the 3:1 conversion proposal that didn’t pass the muster. There were 2,960,576 outstanding common shares during the rejection.

The following Quarter ending on 12/31/23 the outstanding common shares increased to 2,961,056. Only 480 shares were added.

The following Quarter ending on 3/31/24 increased to 3,045,204. An increase of 84,148 shares. During this period of time the proxy vote for a 6:1 conversion was proposed.

The Outstanding common shares as of January 14, 2025 was 6,262,833. That is an increase of 3,217,729 shares. Over a 100 percent increase.

Is the increase of common shares a ploy to get a yes or no vote for the conversion? The investors decided to convert by a total of 719,709 shares. If the plan was to get the Outstanding shares above the 50 percent who would lose and who would win. The common shareholders would lose and the preferred shareholders would win along with the CEO who has a lot of preferred shares. Who are the other 2.3 million shareholders not including the investors that bought shares? They will definitely lose if the conversion is passed in the affirmative.

Conclusion: The answer to the premise will be from the price per share of the common shares. If it goes down drastically, the premise would be that the conversion will be passed. If the common shares price per share increases, then the preferred conversion and the reverse split will not pass muster. IMHO